An exploration of how targeted nanoparticles and artificial intelligence algorithms combine to locate prostate cancer earlier ...

Findings support model in which accelerated biological aging of mammary epithelia may underpin breast cancer susceptibility ...

Prostate cancer remains one of the most common diseases among men, yet current screening methods often lead to unnecessary ...

PanGIA Biotech, Inc. ("PanGIA Biotech" or "Company") announced that two research abstracts have been accepted for ...

TOBY’s urine-based MCED test received FDA Breakthrough Device Designation. This is the first urine-based MCED platform ...

A recent study published in Cell Reports Medicine has identified distinct microbial signatures within the oral cavity and gut ...

TOBY, Inc., a biotechnology company developing non-invasive cancer screening technologies, today announced that the U.S. Food ...

New cfDNA test enables multicancer detection with high accuracy, offering a cost effective approach for early diagnosis and ...

The United States Food and Drug Administration (FDA) issued guidance on its “Breakthrough Devices Program” in 2023.  The ...

This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not include a full text component.